Accenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AI
Accenture has invested in 1910 Genetics through Accenture Ventures to accelerate drug discovery using AI technology. The collaboration combines Accenture's enterprise AI expertise with 1910's proprietary Input-Transform-Output (ITO™) platform, a scalable AI solution for drug discovery. The platform uses federated learning and multiple data streams to enable high-precision target identification, molecule design optimization, and advanced R&D simulation. This partnership aims to help biopharma companies reduce drug development costs, shorten experimental cycles, and increase the probability of clinical success.
Accenture ha investito in 1910 Genetics attraverso Accenture Ventures per accelerare la scoperta di farmaci utilizzando la tecnologia AI. La collaborazione unisce l'esperienza di Accenture nell'AI aziendale con la piattaforma proprietaria Input-Transform-Output (ITO™) di 1910, una soluzione AI scalabile per la scoperta di farmaci. La piattaforma utilizza l'apprendimento federato e molteplici flussi di dati per consentire un'identificazione dei bersagli ad alta precisione, l'ottimizzazione del design delle molecole e simulazioni avanzate di R&S. Questa partnership mira ad aiutare le aziende biofarmaceutiche a ridurre i costi di sviluppo dei farmaci, accorciare i cicli sperimentali e aumentare la probabilità di successo clinico.
Accenture ha realizado una inversión en 1910 Genetics a través de Accenture Ventures para acelerar el descubrimiento de medicamentos utilizando tecnología de IA. La colaboración combina la experiencia de Accenture en IA empresarial con la plataforma Input-Transform-Output (ITO™) de 1910, una solución de IA escalable para el descubrimiento de fármacos. La plataforma utiliza aprendizaje federado y múltiples flujos de datos para permitir una identificación de objetivos de alta precisión, optimización del diseño de moléculas y simulaciones avanzadas de I+D. Esta asociación tiene como objetivo ayudar a las empresas biofarmacéuticas a reducir los costos de desarrollo de medicamentos, acortar los ciclos experimentales y aumentar la probabilidad de éxito clínico.
액센츄어는 인공지능 기술을 활용하여 약물 발견을 가속화하기 위해 1910 유전학에 투자했습니다. 이 협업은 액센츄어의 기업 AI 전문성과 1910의 독점적인 입력-변환-출력 (ITO™) 플랫폼을 결합하며, 이는 약물 발견을 위한 확장 가능한 AI 솔루션입니다. 이 플랫폼은 연합 학습과 여러 데이터 스트림을 사용하여 정확한 목표 식별, 분자 디자인 최적화 및 고급 연구개발 시뮬레이션을 가능하게 합니다. 이 파트너십의 목표는 바이오 제약 회사들이 약물 개발 비용을 줄이고 실험 주기를 단축하며 임상 성공 확률을 높이는 데 도움을 주는 것입니다.
Accenture a investi dans 1910 Genetics par le biais d'Accenture Ventures pour accélérer la découverte de médicaments grâce à la technologie IA. La collaboration allie l'expertise d'Accenture en matière d'IA d'entreprise à la plateforme propriétaire Input-Transform-Output (ITO™) de 1910, une solution IA évolutive pour la découverte de médicaments. La plateforme utilise l'apprentissage fédéré et plusieurs flux de données pour permettre une identification précise des cibles, une optimisation de la conception des molécules et des simulations avancées de R&D. Ce partenariat vise à aider les entreprises biopharmaceutiques à réduire les coûts de développement des médicaments, à raccourcir les cycles expérimentaux et à augmenter la probabilité de succès clinique.
Accenture hat in 1910 Genetics über Accenture Ventures investiert, um die Arzneimittelentdeckung mithilfe von KI-Technologie zu beschleunigen. Die Zusammenarbeit kombiniert die Expertise von Accenture im Bereich der Unternehmens-KI mit der proprietären Input-Transform-Output (ITO™) Plattform von 1910, einer skalierbaren KI-Lösung für die Arzneimittelentdeckung. Die Plattform nutzt föderiertes Lernen und mehrere Datenströme, um eine hochpräzise Zielidentifikation, Moleküldesignoptimierung und fortschrittliche F&E-Simulationen zu ermöglichen. Diese Partnerschaft zielt darauf ab, Biopharma-Unternehmen dabei zu helfen, die Kosten für die Arzneimittelentwicklung zu senken, experimentelle Zyklen zu verkürzen und die Wahrscheinlichkeit des klinischen Erfolgs zu erhöhen.
- Strategic investment in AI-driven drug discovery technology
- Partnership enables enterprise-wide implementation of advanced drug discovery solutions
- Technology potentially reduces drug development costs and timelines
- Platform increases probability of clinical success through data-driven decision making
- None.
Insights
- End-to-end AI solution spanning computational to wet lab processes
- Potential for significant cost reduction in drug development
- Enterprise-wide implementation capabilities
- Cross-therapeutic area applications
- Scalable infrastructure supporting multiple AI models
- Integration of three distinct proprietary data streams
- Automated laboratory processes
- Cross-modality applications
Accenture has invested, through Accenture Ventures, in 1910 Genetics, a biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. (Graphic: Business Wire)
1910’s proprietary Input-Transform-Output (ITO™) platform is a scalable, end-to-end AI solution designed to deliver better drug candidates with applications across all modalities and therapeutic areas. It is a multi-AI agent system comprising hundreds of models that leverages federated learning alongside three proprietary data streams—computational data, wet lab ground truth biological data and wet lab proxy biological data. The platform helps enable drug discovery teams to achieve high precision target identification, optimize molecule design, and conduct advanced simulation throughout the R&D process. By facilitating data-driven decision making, it can increase the probability of clinical success, while shortening experimental iteration cycles and reducing the overall cost of drug development.
“Taking an AI-driven approach is essential in order to reinvent the drug discovery and development process,” said Tom Lounibos, global lead of Accenture Ventures. “Collaborating with 1910 Genetics allows us to integrate our AI expertise with their innovative technology and deliver solutions that can transform drug discovery and improve patient outcomes.”
Accenture’s expertise in scaling AI solutions across enterprises can help biopharma companies smoothly integrate 1910’s AI platform into their existing pipelines. Together, Accenture and 1910 will combine their experience and expertise to help drive breakthroughs in therapeutic development, improve the efficiency of drug discovery, and drive innovation for biopharma companies.
Petra Jantzer, PhD, a senior managing director and global lead of Life Sciences at Accenture, added, “We look forward to joining up our diverse experience in implementing generative AI projects across enterprises and deep expertise in the life sciences sector with 1910 Genetics and its holistic, comprehensive AI platform. Our investment and collaboration support our vision for our biopharma clients to implement tech-enabled drug discovery, automating processes, breaking down silos and increasing productivity.”
“In our discussions with biopharma companies, the desire for AI transformation of their traditional R&D processes is evident,” said Jen Nwankwo, PhD, founder and CEO of 1910 Genetics. “It’s also clear that 1910’s end-to-end AI platform—from in silico to the wet lab and back—addresses the challenges that biopharma companies face with point solutions. By collaborating with Accenture, we aim to bring 1910’s AI platform to biopharma companies as an enterprise-wide horizontal infrastructure that breaks down barriers in data, model, and computing power to accelerate the discovery and development of both small and large molecule therapeutics across all therapeutic areas.”
In conjunction with this announcement, Dr. Petra Jantzer and Tom Lounibos will join the Business Advisory Board of 1910, and Dr. Kailash Swarna, a managing director in Life Sciences at Accenture, and Dr. Cecil Lynch, Biomedical Informatics lead at Accenture, will join the Technology Advisory Board of 1910.
1910 will also join Accenture Ventures’ Project Spotlight, an engagement and investment program for startup companies that create or apply disruptive enterprise technologies.
Terms of the investment were not disclosed.
About Accenture
Accenture is a leading global professional services company that helps the world’s leading organizations build their digital core, optimize their operations, accelerate revenue growth and enhance services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 774,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world’s leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at www.accenture.com.
About 1910 Genetics
1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI that leverages federated learning alongside three proprietary data streams—computational data, wet lab proxy biological data, and wet lab ground truth biological data—to deliver novel drug candidates and software solutions to leading biopharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We recently established a commercial partnership with Microsoft to bring our ITO™ platform to biopharma companies at scale.
1910 was launched in 2021 with a combined seed and Series A funding of
Copyright ©2024 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031043047/en/
Marchell Gillis
Accenture
+1 678 657 7515
marchell.gillis@accenture.com
Keerthi Goutham
Accenture
keerthi.goutham@accenture.com
1910 Genetics PR
media@1910Genetics.com
Source: Accenture
FAQ
What is the purpose of Accenture's investment in 1910 Genetics?
How does 1910 Genetics' ITO platform improve drug discovery?
What role will Accenture play in the collaboration with 1910 Genetics?
